EMA/391491/2014

European Medicines Agency decision

P/0192/2014

of 6 August 2014

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for dupilumab (EMEA-001501-PIP02-13) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0192/2014

of 6 August 2014

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for dupilumab (EMEA-001501-PIP02-13) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Sanofi-Aventis Recherche & Développement on 7 October 2013 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 20 June 2014, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for dupilumab, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for dupilumab, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 3

A waiver for dupilumab, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 4

This decision is addressed to Sanofi-Aventis Recherche & Développement, 1, avenue Pierre Brossolette, 1380 -Chilly-Mazarin, France.

Done at London, 6 August 2014

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/192152/2014

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-001501-PIP02-13

Scope of the application

Active substance(s):

Dupilumab

Condition(s):

Treatment of asthma

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Sanofi-Aventis Recherche & Développement

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Sanofi-Aventis Recherche & Développement submitted for agreement to the European Medicines Agency on 7 October 2013 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 19 November 2013.

Supplementary information was provided by the applicant on 28 March 2014. The applicant proposed modifications to the paediatric investigation plan.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report :

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 20 June 2014

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of asthma

The waiver applies to:

- the paediatric population from birth to less than 6 months of age;
- solution for injection, subcutaneous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of asthma

2.1.1. Indication(s) targeted by the PIP

- Treatment of moderate-to-severe, persistent asthma in paediatric patients 6 to less than 18 years of age that are inadequately controlled with medium to high doses of inhaled corticosteroids in combination with a long-acting beta-agonist.
- Treatment of children 6 months to less than 6 years of age with recurrent severe asthmatic wheezing uncontrolled by inhaled corticosteroids.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 months to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	**Study 1** Development of an age-appropriate strength / presentation for children below 3 years of age.
Non-clinical studies		Not applicable.

Clinical studies	8	**Study 2** Open-label study to characterize the safety and pharmacokinetics (PK) of a single administration of dupilumab in paediatric patients 6 years to less than 18 years of age. **Study 3** Randomized, double-blind, placebo controlled study to assess the efficacy and long term safety of dupilumab in adolescent (and in adult) patients with moderate to severe persistent uncontrolled asthma. **Study 4** Randomized, double-blind, placebo controlled study to assess the efficacy and long term safety of dupilumab in adolescent (and in adult) patients with moderate to severe persistent uncontrolled asthma. **Study 5** Open-Label study to characterize the safety and PK of a single administration of dupilumab in paediatric patients 6 months to less than 6 years of age. **Study 6** Randomized, double-blind, placebo controlled study to assess the efficacy and long term safety of dupilumab in children 6 to less than 12 years old with moderate to severe, persistent uncontrolled asthma. **Study 7** Randomized, double-blind, placebo controlled study to assess the efficacy and long term safety of dupilumab in children 6 months to less than 6 years old with recurrent severe asthmatic wheezing uncontrolled by inhaled corticosteroids. **Study 8** Open-label follow-up study to evaluate the long-term safety and tolerability of dupilumab in adolescent (and in adult) patients who participated in previous dupilumab asthma clinical studies. **Study 9** Open-label follow-up study to evaluate the long-term safety and tolerability of dupilumab in children 6 months to less than 12 years patients who participated in previous dupilumab asthma clinical studies.
Extrapolation, modelling and simulation studies	1	**Study 10** Modelling and simulation study to determinate the appropriate dose /regimen for the efficacy and safety studies in children 6 months to less than 18 years of age.
Other studies		Not applicable.
Other measures		Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By October 2025
Deferral for one or more measures contained in the paediatric investigation plan:	Yes